The European Lead Factory (ELF) is a collaborative public-private partnership aiming to deliver innovative drug discovery starting points. The ELFgives free access to up to 550,000 novel compounds, a unique industry-standard uHTS platform, and much more.

The success of the ELF approach has been widely acknowledged and the output has shown to be of high quality, worth following up and investment-ready. Funding for further development has been secured for several programmes, and by March 2018 two programmes have led to partnering deals being closed between the Programme Owner and an established pharmaceutical company.

A number of projects are now available for partnering.

The available projects are here.